Eisai successfully defends multiple antitrust class actions arising from its enforcement of Aciphex patents
Clients Eisai Co., Ltd.
Jones Day successfully defended Eisai Co., Ltd. against antitrust class actions brought in New York and Mississippi on behalf of nationwide classes of direct and indirect purchasers of Esai's proton pump inhibitor drug, Aciphex. The plaintiffs alleged that Esai's enforcement of its patents listed for Aciphex in Hatch-Waxman infringement litigation constituted monopolization and attempted monopolization. Rather than litigate motions to dismiss and for sanctions, all plaintiffs agreed to voluntary dismissal of their claims.
Meijer, Inc. v. Eisai Co., Case No. 06 CV 11511 (S.D.N.Y.)